Home › Trial NCT05546866
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
- Trial IDNCT05546866
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorAstraZeneca
- Enrollment51
- Start date2023-02-09
- ConditionsNon-small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.